Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 592

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Fenaux, P., Giagounidis, A. A. N., Selleslag, D., Beyne‐Rauzy, O., Mufti, G. J., Mittelman, M., Muus, P., Boekhorst, P. A. W. T., Sanz, G. F., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 497

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

Itzykson, R., Kosmider, O., Cluzeau, T., Mas, V. M., Dreyfus, F., Beyne‐Rauzy, O., Quesnel, B., Vey, N., Gelsi‐Boyer, V., Raynaud, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.71 · Cited by 480

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463

A simple p53 functional assay for screening cell lines, blood, and tumors.

Flaman, J., Frébourg, T., Moreau, V., Charbonnier, F., Martin, C., Chappuis, P. O., Sappino, A. P., Limacher, I. M., Bron, L. P., & Benhattar, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3963 · Cited by 455

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne‐Rauzy, O., Turlure, P., Vey, N., Récher, C., Dartigeas, C., Legros, L., et al. (2010) · Blood · doi:10.1182/blood-2010-06-289280 · Cited by 381

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

Shen, L.-L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S. S., Zhu, W., Pierce, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4781 · Cited by 348

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

Bejar, R. L., Lord, A. M., Stevenson, K. E., Bar‐Natan, M., Pérez-Ladaga, A., Zaneveld, J. E., Wang, H., Caughey, B. A., Stojanov, P., Getz, G. A., et al. (2014) · Blood · doi:10.1182/blood-2014-06-582809 · Cited by 575

Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes

Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, C., Bauer, M., Davies, F. E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0196-8 · Cited by 457

Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 428

Eprenetapopt Plus Azacitidine in TP53 -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Cluzeau, T., Sebert, M., Rahmé, R., Cuzzubbo, S., Lehmann-Che, J., Madelaine, I., Peterlin, P., Bève, B., Attalah, H., Chermat, F., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02342 · Cited by 279

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0351-2 · Cited by 259

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

Sallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.304 · Cited by 231

Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management

Garcia‐Manero, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26984 · Cited by 241

Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management

Bravo, G. M., & Garcia‐Manero, G. (2017) · American Journal of Hematology · doi:10.1002/ajh.24930 · Cited by 212

Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management

Garcia‐Manero, G., Chien, K. S., & Bravo, G. M. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 192

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions

Valent, P., Orazi, A., Savona, M. R., Patnaik, M. M., Onida, F., van de Loosdrecht, A. A., Haase, D. T., Haferlach, T., Elena, C., Pleyer, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.222059 · Cited by 141

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001101 · Cited by 133

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., Ohanian, M., Dinardo, C. D., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30182-0 · Cited by 120

The molecular pathogenesis of the myelodysplastic syndromes

Pellagatti, A., & Boultwood, J. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12515 · Cited by 120

Mutations of myelodysplastic syndromes (MDS): An update

Ganguly, B. B., & Kadam, N. N. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.04.009 · Cited by 108

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

Garcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer · doi:10.1002/cncr.30533 · Cited by 104

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

Takahashi, K., Patel, K. P., Bueso-Ramos, C., Zhang, J., Gumbs, C. E., Jabbour, E. J., Kadia, T. M., Andreff, M., Konopleva, M. Y., Dinardo, C. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7290 · Cited by 103

TP 53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation

Middeke, J. M., Herold, S., Rücker‐Braun, E., Berdel, W. E., Stelljes, M., Kaufmann, M., Schäfer‐Eckart, K., Baldus, C. D., Stuhlmann, R., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13912 · Cited by 101

Pharmacological reactivation of p53 in the era of precision anticancer medicine

Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 97

Novel drugs for older patients with acute myeloid leukemia

Bravo, G. M., & Garcia‐Manero, G. (2014) · Leukemia · doi:10.1038/leu.2014.244 · Cited by 82

What have we learned about TP53-mutated acute myeloid leukemia?

Shahzad, M., Amin, M. K., Daver, N. G., Shah, M. V., Hiwase, D., Arber, D. A., Kharfan‐Dabaja, M. A., & Badar, T. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01186-5 · Cited by 88

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Hunter, A. M., Komrokji, R. S., Yun, S., Al Ali, N., Chan, O., Song, J., Hussaini, M., Talati, C., Sweet, K. L., Lancet, J. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003508 · Cited by 76

The genetic and molecular pathogenesis of myelodysplastic syndromes

Shallis, R. M., Ahmad, R., & Zeidan, A. M. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13092 · Cited by 76

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature

Kuendgen, A., Müller‐Thomas, C., Lauseker, M., Haferlach, T., Urbaniak, P., Schroeder, T. A., Brings, C., Wulfert, M., Meggendorfer, M., Hildebrandt, B., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25328 · Cited by 74

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

Molica, M., Mazzone, C., Niscola, P., & de Fabritiis, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.610820 · Cited by 75

Acute Myeloid Leukemia With Myelodysplasia-Related Changes

Vardiman, J. W., & Reichard, K. K. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcp58rsmfrhlhhh · Cited by 70

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome

Jung, S., Kim, Y., Yim, S., Kim, H. J., Kwon, Y.-R., Hur, E., Goo, B.-K., Choi, Y., Lee, S. H., Chung, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10526 · Cited by 70

Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia

Daher-Reyes, G. S., Merchán, B., & Yee, K. W. L. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1667331 · Cited by 66

Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Poiré, X., Labopin, M., Maertens, J. A., Yakoub‐Agha, I., Blaise, D., Ifrah, N., Socié, G., Gedde-Dhal, T., Schaap, N. P., Cornelissen, J. J., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0393-3 · Cited by 62

Clinical decision-making and treatment of myelodysplastic syndromes

Hellström‐Lindberg, E., & Kröger, N. M. (2023) · Blood · doi:10.1182/blood.2023020079 · Cited by 61

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

Beličková, M., Veselá, J., Jonasova, A. T., Pejsova, B., Votavová, H., Merkerová, M. D., Zemanová, Z., Březinová, J., Mikulenková, D., Lauermannová, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9200 · Cited by 56

Hypomethylating Agents as a Therapy for AML

Gardin, C., & Dombret, H. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0363-4 · Cited by 59

Azacitidine in adult patients with acute myeloid leukemia

Schuh, A. C., Döhner, H., Pleyer, L., Seymour, J. F., Fenaux, P., & Dombret, H. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.05.010 · Cited by 57

Decitabine inTP53-Mutated AML

Welch, J. S., Petti, A. A., & Ley, T. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1616062 · Cited by 56

TP 53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis

Loghavi, S., Al‐Ibraheemi, A., Zuo, Z., Garcia‐Manero, G., Yabe, M., Wang, S. A., Kantarjian, H. M., Yin, C. C., Miranda, R. N., Luthra, R., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13529 · Cited by 52

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline

de Haas, V., Ismaila, N., Advani, A. S., Arber, D. A., Dabney, R. S., Patel‐Donnelly, D., Kitlas, E., Pieters, R., Pui, C., Sweet, K. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01468 · Cited by 55

Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)

Yun, S., Geyer, S. M., Komrokji, R. S., Al Ali, N. H., Song, J., Hussaini, M., Sweet, K. L., Lancet, J. E., List, A. F., Padron, E., et al. (2021) · Leukemia · doi:10.1038/s41375-020-0997-4 · Cited by 49

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 53

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms

Shah, M. V., Tran, E. N. H., Shah, S., Chhetri, R., Baranwal, A., Ładoń, D., Shultz, C. T., Al‐Kali, A., Brown, A. L., Chen, D., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00821-x · Cited by 50

Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53- mutated MDS/AML

Nawas, M. T., & Kosuri, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010417 · Cited by 49

TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited

Shin, D.-Y. (2023) · Cancers · doi:10.3390/cancers15194816 · Cited by 46

Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

Talati, C., Sallman, D. A., & List, A. F. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.06.003 · Cited by 45

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

Cedena, M., Rapado, I., Santos‐Lozano, A., Ayala, R. M., Onecha, E., Abáigar, M., Such, E., Ramos, F., Cervera, J., Díez‐Campelo, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22157 · Cited by 45

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death

Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201910852 · Cited by 41

Integrating mutation variant allele frequency into clinical practice in myeloid malignancies

Sallman, D. A., & Padron, E. (2016) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2016.04.003 · Cited by 39

Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin

Wang, Y., Liu, Y., Bailey, C., Zhang, H., He, M., Sun, D., Zhang, P., Parkin, B., Baer, M. R., Zheng, P., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1201-z · Cited by 38

Overexpression of GYS1, MIF, and MYC Is Associated With Adverse Outcome and Poor Response to Azacitidine in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Falantes, J. F., Trujillo, P., Piruat, J. I., Calderón, C., Márquez-Malaver, F. J., Martín-Antonio, B., Millán‐Uclés, Á., Gómez, M., González, J., Martino, M. L., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.10.003 · Cited by 38

An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia

Solly, F., Koering, C., Mohamed, A. M., Maucort‐Boulch, D., Robert, G., Auberger, P., Flandrin‐Gresta, P., Adès, L., Fenaux, P., Kosmider, O., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2304 · Cited by 37

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status

Aldoss, I. T., Pham, A. T., Li, S. M., Gendzekhadze, K., Afkhami, M., Telatar, M., Hong, H., Padeganeh, A., Bedell, V., Cao, T. M., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.172544 · Cited by 37

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings

Cumbo, C., Tota, G., Anelli, L., Zagaria, A., Specchia, G., & Albano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103432 · Cited by 39

Significance of oncogenes and tumor suppressor genes in AML prognosis

Kavianpour, M., Ahmadzadeh, A., Shahrabi, S., & Saki, N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5067-1 · Cited by 37

Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies

Komrokji, R. S., Swern, A. S., Grinblatt, D. L., Lyons, R. M., Tobiasson, M., Silverman, L. R., Sayar, H., Vij, R., Fliss, A., Tu, N., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0215 · Cited by 37

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms

Schimmer, R. R., Kovtonyuk, L. V., Klemm, N., Fullin, J., Stolz, S. M., Mueller, J. O., Caiado, F., Kurppa, K. J., Ebert, B. L., Manz, M. G., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005859 · Cited by 34

Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

Xu, Y., Jiang, P., Xu, Z., & Ye, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1348852 · Cited by 33

Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes

Wang, H., Li, Y., Lv, N., Li, Y., Wang, L., & Yu, L. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3464-9 · Cited by 32

Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future

Choi, J., Shukla, M., & Abdul‐Hay, M. (2023) · Acta Haematologica · doi:10.1159/000531628 · Cited by 34

TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation

Zhao, D., Zarif, M., Zhou, Q., Capo‐Chichi, J., Schuh, A. C., Minden, M. D., Atenafu, E. G., Kumar, R., & Chang, H. (2023) · Cancers · doi:10.3390/cancers15123210 · Cited by 29

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments

Granowicz, E. M., & Jonas, B. A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s265637 · Cited by 31

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms

Nannya, Y., Tobiasson, M., Sato, S., Bernard, E., Ohtake, S., Takeda, J., Creignou, M., Zhao, L., Kusakabe, M., Shibata, Y., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009564 · Cited by 29

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms

Lee, W., Lin, C., Tsai, C., Tien, F., Lo, M., Tseng, M., Kuo, Y., Yu, S., Liu, M.-C., Yuan, C., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01031-9 · Cited by 30

Chronic myelomonocytic leukemia - a review

Thomopoulos, T. P., Bouhla, A., Papageorgiou, S. G., & Pappa, V. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2021.1860004 · Cited by 27

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

Duong, V. H., Ruppert, A. S., Mims, A. S., Borate, U., Stein, E. M., Baer, M. R., Stock, W., Kovacsovics, T. J., Blum, W. G., Arellano, M. L., et al. (2023) · Cancer · doi:10.1002/cncr.34780 · Cited by 27

Potential Relationship between Inadequate Response to DNA Damage and Development of Myelodysplastic Syndrome

Zhou, T., Chen, P., Gu, J. H., Bishop, A. J. R., Scott, L., Hasty, P., & Rebel, V. I. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16010966 · Cited by 26

The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms

Briest, F., & Grabowski, P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.006 · Cited by 26

Utx loss causes myeloid transformation

Zheng, L., Xu, L., Xu, Q., Yu, L., Zhao, D., Chen, P., Wang, W., Wang, Y., Han, G., & Chen, C. D. (2018) · Leukemia · doi:10.1038/s41375-018-0011-6 · Cited by 26

PP2A: The Achilles Heal in MDS with 5q Deletion

Sallman, D. A., Sheng, W., & List, A. F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00264 · Cited by 26

Induction of senescence in cancer cells by 5′-Aza-2′-deoxycytidine: Bioinformatics and experimental insights to its targets

Putri, J. F., Widodo, N., Sakamoto, K., Kaul, S. C., & Wadhwa, R. (2017) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2017.08.003 · Cited by 25

Characterization of TP 53 mutations in low‐grade myelodysplastic syndromes and myelodysplastic syndromes with a non‐complex karyotype

Wang, W., Routbort, M. J., Tang, Z., Ok, C. Y., Patel, K. P., Daver, N. G., Garcia‐Manero, G., Medeiros, L. J., & Wang, S. A. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12971 · Cited by 26

British Society for Haematology guidelines for the management of adult myelodysplastic syndromes

Killick, S. B., Ingram, W. A., Culligan, D. J., Enright, H., Kell, J., Payne, E. M., Krishnamurthy, P., Kulasekararaj, A. G., Raghavan, M., Stanworth, S. J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17612 · Cited by 25

Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulation

Marchal, C., de Dieuleveult, M., Saint‐Ruf, C., Guinot, N., Ferry, L., Saad, S. T. O., Lazarini, M., Defossez, P., & Miotto, B. (2018) · Oncogenesis · doi:10.1038/s41389-018-0092-0 · Cited by 23

Targeting TP53 Mutations in Myelodysplastic Syndromes

Hunter, A. M., & Sallman, D. A. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.11.004 · Cited by 25

Can we predict responsiveness to hypomethylating agents in AML?

Stomper, J., & Lübbert, M. (2019) · Seminars in Hematology · doi:10.1053/j.seminhematol.2019.02.001 · Cited by 22

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia

Vidal, V., Robert, G., Goursaud, L., Durand, L., Ginet, C., Karsenti, J. M., Luciano, F., Gastaud, L., Garnier, G., Braun, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17482 · Cited by 22

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia

Becker, H., Pfeifer, D., Ihorst, G., Pantić, M., Wehrle, J., Rüter, B. H., Bullinger, L., Hackanson, B. W., Germing, U., Kuendgen, A., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04082-7 · Cited by 21

The genetics of myelodysplastic syndromes and the opportunities for tailored treatments

Kontandreopoulou, C., Kalopisis, K., Viniou, N., & Diamantopoulos, P. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.989483 · Cited by 23

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML

Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere · doi:10.1002/hem3.70164 · Cited by 26

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine

Bories, P., Prade, N., Lagarde, S., Cabarrou, B., Largeaud, L., Plenecassagnes, J., Luquet, I., Mas, V. M., Filleron, T., Cassou, M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238795 · Cited by 20

TP53 in Myelodysplastic Syndromes

Jiang, Y., Gao, S., Soubise, B., Douet‐Guilbert, N., Liu, Z., & Troadec, M. (2021) · Cancers · doi:10.3390/cancers13215392 · Cited by 22

TP53 in AML and MDS: The new (old) kid on the block

Marks, J. A., Wang, X., Fenu, E. M., Bagg, A., & Lai, C. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101055 · Cited by 20

Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis

Gonçalves, A. C., Alves, R., Baldeiras, I., Cortesão, E., Carda, J. P., Branco, C. C., Oliveiros, B., Loureiro, L., Pereira, A., Costa, N., et al. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22478 · Cited by 20

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML

Kubasch, A. S., & Platzbecker, U. (2018) · Cancers · doi:10.3390/cancers10060158 · Cited by 20

The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia

Shallis, R. M., Boddu, P. C., Bewersdorf, J. P., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100639 · Cited by 19

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Cluzeau, T., Loschi, M. L., Fenaux, P., Komrokji, R. S., & Sallman, D. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810105 · Cited by 20

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

Ahmadi, S. E., Rahimian, E., Rahimi, S., Zarandi, B., Bahraini, M., Soleymani, M., Safdari, S. M., Shabannezhad, A., Jaafari, N., & Safa, M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00676-9 · Cited by 22

Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study

Lee, B., Kang, K., Jeon, M. J., Yu, E. S., Kim, D. S., Choi, H., Lee, S. R., Sung, H. J., Kim, B. S., Choi, C. W., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56642-1 · Cited by 19

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

Ceder, S., Eriksson, S. E., Liang, Y. Y., Cheteh, E. H., Zhang, S. M., Fujihara, K. M., Bianchi, J., Bykov, V. J. N., Abrahmsen, L., Clemons, N. J., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03988-y · Cited by 18

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Dezern, A. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.308 · Cited by 18

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia

Shapiro, R. M., & Lazo‐Langner, A. (2018) · BMC Hematology · doi:10.1186/s12878-017-0094-8 · Cited by 18

Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine

Desoutter, J., Gay, J., Berthon, C., Adès, L., Gruson, B., Geffroy, S., Plantier, I., Marceau‐Renaut, A., Hélevaut, N., Fernandes, J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.314 · Cited by 17

Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia

Gopalakrishnapillai, A., Kolb, E. A., McCahan, S. M., & Barwe, S. P. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.05.004 · Cited by 17

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine

Sébert, M., Komrokji, R. S., Sekeres, M. A., Prébet, T., Cluzeau, T., Santini, V., Gyan, E., Sanna, A., Ali, N. H. A., Hobson, S., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.10.013 · Cited by 16

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes

McGraw, K. L., Cluzeau, T., Sallman, D. A., Basiorka, A. A., Irvine, B. A., Zhang, L., Epling‐Burnette, P. K., Rollison, D. E. M., Mallo, M., Sokol, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5255 · Cited by 15

p53 as an Effector or Inhibitor of Therapy ResponsePreprint

Ablain, J., Poirot, B., Esnault, C., Lehmann‐Che, J., & de Thé, H. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026260 · Cited by 15

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes

Loschi, M. L., Fenaux, P., & Cluzeau, T. (2022) · Cancers · doi:10.3390/cancers14184519 · Cited by 16

A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics

Nishiwaki, S., Ito, M., Watarai, R., Okuno, S., Harada, Y., Yamamoto, S., Suzuki, K., Kurahashi, S., Iwasaki, T., & Sugiura, I. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.11.014 · Cited by 13

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis

Middeke, J. M., Teipel, R., Röllig, C., Stasik, S., Zebisch, A., Sill, H., Krämer, M., Scholl, S., Hochhaus, A., Jost, E., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1864354 · Cited by 13

How I treat higher-risk MDS

Mina, A. A., & Komrokji, R. S. (2025) · Blood · doi:10.1182/blood.2024025271 · Cited by 15

Potential use of compounds from sea cucumbers as MDM2 and CXCR4 inhibitors to control cancer cell growth

Wargasetia, T. L., Permana, S., & Widodo, N. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6588 · Cited by 12

Analysis of clinical and molecular features of MDS patients with complex karyotype in China

Ren, Y., Mei, C., Ye, L., Luo, Y., Zhou, X., Yang, H., Lin, P., Xu, W., Ma, L., Jin, J., et al. (2018) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2018.11.006 · Cited by 11

Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine

Bally, C., Adès, L., Renneville, A., Preudhomme, C., Mozziconacci, J., de Thé, H., Lehmann‐Che, J., & Fenaux, P. (2012) · Blood · doi:10.1182/blood.v120.21.1706.1706 · Cited by 5

Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Müller‐Thomas, C., Rudelius, M., Rondak, I., Haferlach, T., Schanz, J., Schmidt, B., Kremer, M., Germing, U., Platzbecker, U., Peschel, C., et al. (2013) · Blood · doi:10.1182/blood.v122.21.2797.2797 · Cited by 2

P-006 Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA)

Bally, C., Adès, L., Renneville, A., Mozziconacci, J., Preudhomme, C., Dethé, H., Lehmann‐Che, J., & Fenaux, P. (2013) · Leukemia Research · doi:10.1016/s0145-2126(13)70055-9

PF553 CLONES WITH COMPLEX ABERRATIONS AND TP53 MUTATIONS RESPOND TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA

Ganster, C., Mazzeo, P., Elmaagacli, A. H., Dierks, S., Shirneshan, K., Scharnberg, P., Martin, R., Rittscher, K., Götze, K. S. S., Glaß, B., et al. (2019) · HemaSphere · doi:10.1097/01.hs9.0000560508.32787.fe

TP 53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

Kulasekararaj, A. G., Smith, A. E., Mian, S. A., Mohamedali, A. M., Krishnamurthy, P., Lea, N. C., Gäken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12203 · Cited by 250